Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | HTR6 | P50406 | 8/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25190824 | 0.91 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL1669689 | 0.83 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL2273205 | 0.83 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL17628727 | 0.83 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL29428770 | 0.83 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL28735217 | 0.83 | HTR6 (0.46) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL29428833 | 0.83 | CYP2C19 (0.44) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL17628721 | 0.81 | CYP2C19 (0.41) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL12612708 | 0.80 | CYP2C19 (0.41) | CYP2C19METHTR6KMT2AMEN1 | |
| SCHEMBL24166171 | 0.79 | GAA (0.43) | CYP2C19METHTR6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220064165-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-03-03 | — | — | US | disclosed |
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-01-06 | — | — | US | disclosed |
| WO-2022006456-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002299-A1 | TRICYCLIC PYRIDONE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CYP2C19 327/4885MET 1748/4885HTR6 1892/4885 |
| US-11767323-B2 | Tricyclic pyridone compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CYP2C19 327/4885MET 1748/4885HTR6 1892/4885 |
| US-20220064165-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | CYP2C19 1141/4885MET 1109/4885HTR6 4357/4885 |
| US-11661422-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | CYP2C19 1141/4885MET 1109/4885HTR6 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.